ALN-AAT: Development discontinued

Alnylam will discontinue development of ALN-AAT after interim data from a single-blind, U.K. Phase I/II trial in 26 healthy volunteers showed that single subcutaneous doses of ALN-AAT led to transient, asymptomatic and dose-dependent elevations in liver enzymes in 3 subjects. Additionally, a single 6 mg/kg dose of ALN-AAT led to a mean maximal knockdown of serum AAT of 83.9% and a mean AAT knockdown at about 6 months of 75%. Subjects received placebo, a single dose of 0.1-6 mg/kg ALN-AAT or ...